OrthoPediatrics Corp. (KIDS) Dividend History

OrthoPediatrics Corp. (KIDS) is a medical device company focused on providing specialized orthopedic solutions for children. It develops and markets innovative implants and surgical products aimed at treating pediatric orthopedic conditions, including limb deformities, fractures, and spinal disorders. The company emphasizes minimally invasive procedures and tailored treatments to improve outcomes for pediatric patients.

2850 Frontier Drive, Warsaw, IN, 46582
Phone: 574-268-6379
Website: https://www.orthopediatrics.com

Dividend History

OrthoPediatrics Corp. currently does not pay dividends

Company News

  • OrthoPediatrics Corp. Announces Distribution Agreement with MY01 Inc.

    OrthoPediatrics Corp. announced a distribution partnership with MY01 to expand access to Continuous Perfusion Sensing Technology for diagnosing acute compartment syndrome in children, focusing on improving trauma monitoring and patient outcomes.

    GlobeNewswire Inc.
  • OrthoPediatrics (KIDS) Q2 Revenue Up 16%

    OrthoPediatrics reported Q2 2025 revenue of $61.1 million, slightly below estimates, with continued growth in pediatric orthopedic devices. The company maintained its full-year revenue guidance and showed improvements in adjusted EBITDA, though still experiencing net losses.

    The Motley Fool
  • Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors

    Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a company known for its development in biosensors. The acquisition is expected to strengthen Bruker's position in the pharma and biotech industries by leveraging its leading high-throughput Surface Plasmon Resonance portfolio and Dynamic Biosensors' unique instruments.

    Benzinga
    Featured Companies: AXGN BRKR TMDX
  • OrthoPediatrics (KIDS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

    OrthoPediatrics reported Q2 2024 revenue of $52.8 million, up 33.5% year-over-year, and EPS of -$0.23 compared to -$0.19 a year ago. The company's performance across key product categories was mixed compared to analyst estimates.

    Zacks Investment Research
Page data last updated 09/06/2025 15:41:41 UTC